What is Nuclein?
Founded in 2017 by biotechnology veterans Alan Blake and Dr. Richard Crockett, Nuclein is dedicated to revolutionizing infectious disease testing. The company's core mission is to develop a portable, disposable, all-in-one self-test device capable of delivering sample-to-answer results within an hour, without the need for laboratory mail-in services. This technology aims to provide rapid, accessible diagnostic capabilities, potentially transforming how infectious diseases are identified and managed in various settings.
How much funding has Nuclein raised?
Nuclein has raised a total of $20.9M across 2 funding rounds:
Series A
$5.6M
Series B
$14M
Series A (2020): $5.6M, investors not publicly disclosed
Series B (2021): $14M led by Trinity Private Equity Group
Key Investors in Nuclein
Trinity Private Equity Group
Trinity Private Equity Group is a private equity firm that likely focuses on providing growth capital and strategic support to companies within the healthcare and technology sectors, aligning with Nuclein's mission.
What's next for Nuclein?
The recent major strategic investment signals a pivotal phase for Nuclein, likely enabling the company to scale its operations, advance its product development pipeline, and potentially pursue regulatory approvals. This enterprise-level funding suggests a focus on commercialization and market penetration, positioning Nuclein to address the growing demand for rapid diagnostic solutions in both clinical and consumer markets. The company's trajectory points towards becoming a key player in the decentralized diagnostics sector.
See full Nuclein company page
